Borghesani M et al. Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasms. J Natl Compr Canc Netw 2024;22(5):e247005. Abstract

Capdevila J et al. Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial. ASCO 2025;Abstract 3004.

Lu M et al. Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial. ASCO 2025;Abstract 2500.

Mountzios G et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 2025;393(4):349-61. Abstract

Sands S et al. Datopotamab deruxtecan in advanced or metastatic non–small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 Study. J Clin Oncol 2025;43(10):1254-65. Abstract

Serrano AG et al. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 2024;8(1):268. Abstract

Sorbye H et al. Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. Br J Cancer 2025;133(3):316-24. Abstract

Thummalapalli R et al. Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms. medRxiv [Preprint] 2025. Abstract